Performance

AKTS -26.92%

Watchlist

Select an item

RETURNS	1D	YTD	1Y	5Y Ann.	Max DD	Sharpe	Div. Yield
AKTS	+3.48%	-26.92%*	-26.92%*	—	-54.73%*	-0.28*	0.00%*

Summary

AKTS at a glance

AKTS returned -26.92% since Jan 9, 2026. Its worst drop since then was -54.73%, smaller than 17% of stocks on Redstone, and its Sharpe ratio of -0.28 beats 17% of stocks on Redstone. It hasn't paid a dividend since it listed.

Ranking

How AKTS ranks

Dividend Yield Rank *

Current Drawdown

-49.21%

Rolling Volatility

65.78%

Actions

Metrics

Risk Indicators*

Alpha-30.58%

Beta1.49x

Sharpe-0.28

Sortino-0.38

Omega0.96

Calmar-0.49

Martin-0.74

Profile

About AKTS

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.

Sector: Health Care
Industry: Pharmaceutical Preparations
Market cap: $910M
Listed: Jan 2026
Employees: 79
Headquarters: Boston, MA
Website: aktisoncology.com

Comparisons

AKTS: Aktis Oncology, Inc.

AKTS at a glance

How AKTS ranks

Current Drawdown

Rolling Volatility

About AKTS

Related comparisons